Clinical Trial: Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment

U.S., March 4 -- ClinicalTrials.gov registry received information related to the study (NCT07444567) titled 'Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment' on Feb. 17.

Brief Summary: The rationale of the roll-over study (ROSY) is to provide continuous access to study treatment for participants who have completed or exited a parent study and are deemed appropriate for continued benralizumab treatment, as judged by the Investigator, while monitoring long-term safety and tolerability of benralizumab.

Study Start Date: March 27

Study Type: INTERVENTIONAL

Condition: Asthma Eosinophilic Granulomatosis With Polyangiitis (EGPA) Hypereosinophilic Sy...